EGFR and neoplasm: First, although our NMA suggests that first-generation EGFR-TKIs plus chemotherapy is the most favorable strategy for non-elderly advanced EGFR-mutated NSCLC patients, no RCTs have compared the efficacy of combing second or third generation EGFR-TKIs and chemotherapy to other anti-tumor treatments.